Nevertheless, the overall response rates of R/M NPC to ICI immunotherapy fall between 18% and 26%, indicating that utilizing the intratumoral expression of PD‐L1 or tumour mutation burden in assessing the clinical response of R/M NPC to ICI immunotherapy is insufficient.9 This evidence concerns the gene CD274 and nasopharyngeal carcinoma.